Background: Both sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like
peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in placebo …

Liver disease is the spectrum of liver damage ranging from simple steatosis called as
nonalcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC). Clinically …

Objectives This study evaluated the application of a biomarker-based risk score to identify
individuals with dysglycemia who are at high risk for incident heart failure (HF) and to inform …

Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-
1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough …

Type 2 diabetes mellitus (T2DM) is a worldwide major health burden and heart failure (HF)
is the most common cardiovascular (CV) complication in affected patients. Therefore …

Introduction: Obesity is a growing threat to public health, increasing risks of numerous
diseases and mortality, and impairing quality of life. If current trends continue, more than 1.1 …

Aim There are no approved drugs for the treatment of non-alcoholic fatty liver disease
(NAFLD). However, many randomized controlled trials (RCT) have examined the effect of …

Adult-onset autoimmune (AOA) diabetes pathophysiology starts with immune changes,
followed by dysglycaemia and overt disease. AOA diabetes can occur as classic type 1 …

Abstract Background/Aim Non‐alcoholic fatty liver disease (NAFLD) affects approximately
25% of the global adult population. The aim of this narrative review is to describe the …

The obesity pandemic is accompanied by increased risk of developing metabolic syndrome
(MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic …